Syntex' low dose Tri-Norinyl
Triphasic oral contraceptive product has been approved by FDA, firm said April 13. Maintaining that the product is "the lowest dose (overall hormonal content) multiphasic regimen" in the U.S., Syntex said that by varying the hormone content through the reproductive cycle unwanted side-effects such as breakthrough bleeding and spotting are reduced. Tri-Norinyl is available in either 21 or 28 day regimens. Price to whslrs. will be the same as for Brevicon and Norinyl, the firm's other low dose oral contraceptive products.
You may also be interested in...
US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.